跳到正文
Giampaolo Bianchini· @BianchiniGP · X·· 1 天前评分70

POSTMONARCH

正文 · 机器翻译

🔥 Abema + fulvestrant在1L CDK4/6i/AI治疗后改善PFS、PFS2及化疗启动时间;OS数值上升

👉 在CDK4/6i治疗后,CDK靶向治疗仍然有效,但这并非类效应!

✅ Abema(postMONARCH、EMBER-3)、atirmociclib(FourLight-1)、ribo(MAINTAIN)
⛔ Palbo(PACE、PALMIRA)

#ESMO26

50 浏览 · 1 赞 · 0 转发 · 0 回复

会议摘要
1RO按 Rapid oral 1: Breast cancer, advanced stage 对上

Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy

https://esmocongress.esmo.org

来源:Giampaolo Bianchini · x.com

CBACBA Frontier Insights (CFI)美国华人生物医药科技协会(CBA)www.cba-usa.org